Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

CompletedOBSERVATIONAL

Enrollment

158,310

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

March 6, 2025

Study Completion Date

March 6, 2025

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

New use of semaglutide injection

New use of semaglutide injection dispensing claim is used as the exposure.

DRUG

New initiation of sitagliptin

New initiation of sitagliptin dispensing claim is used as the reference.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT06659744 - Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims | Biotech Hunter | Biotech Hunter